Trial Profile
A single center of large urology group study to evaluate the effect of combined seqential treatment of sipuleucel-T followed by enzalutamide in patients with metastatic chemo-naive castration-resistant prostate cancer.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 25 Aug 2015
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 25 Aug 2015 New trial record
- 03 Jun 2014 Interim results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.